. Author manuscript; available in PMC: 2011 Oct 1.

Published in final edited form as: Circ Cardiovasc Genet. 2010 Aug 21;3(5):462–467. doi: 10.1161/CIRCGENETICS.110.950667

Table 2.

Adjusted fasting triglyceride (FTG) concentrations by APOE genotype group before and after fenofibrate treatment (160 mg/day).

	ε3/ε3	ε4 Carrier	ε2 Carrier
Pre-Fenofibrate	N=666	N=289	N=117
FTG ^* (mg/dL)	109.3 (104, 115)	120.9 (113, 129)‡^b	130.5 (118, 144)‡^c
Post-Fenofibrate	N=454	N=203	N=81
FTG^*^† (mg/dL)	75.9 (72,80)	81.9 (76,88)	85.1 (77, 95) ‡^a

Values are least squares means (95% CIs) adjusted for age, gender, waist circumference, and family relationship

^†

Additionally adjusted for area under the serum fenofibric acid curve

^‡

Significantly higher fasting triglyceride concentration when compared to the reference genotype (ε3/ε3). Superscripts a, b and c signify P<0.05, P<0.01and P<0.001, respectively